Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) unit Teva Women's Health Inc. today reported positive results from the Phase III clinical trial of its Quartette oral contraceptive. The study found that Quartette was effective and has a safety profile similar to that of other oral contraceptives.
The clinical trial enrolled 3,701 sexually active women aged 18-40, 2,144 of whom completed the one-year study. The efficacy of the Quartette pill was measured using the Pearl Index for reporting pregnancy rates, which was 2.92, based on 65 pregnancies that occurred after the onset of treatment and within seven days after the last tablet in women aged 18-35 years old. The measurement excluded cycles in which another method of birth control was used.
Teva Women’s Health VP and general manager US Brand Pharmaceuticals Marty Berndt said, “Quartette is an exciting advancement for women of reproductive age, as it offers them a unique contraceptive option. It also builds upon our heritage of providing women with innovative, extended-cycle contraceptive products, further reflecting our longtime commitment to women’s reproductive health."
Teva presented the data at the 68th Annual Meeting of the American Society of Reproductive Medicine.
Published by Globes [online], Israel business news - www.globes-online.com - on October 25, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012